Research progress of drugs for the treatment of atopic dermatitis
10.12173/j.issn.1005-0698.202401064
- VernacularTitle:特应性皮炎治疗药物的研究进展
- Author:
Rui ZOU
1
;
Juan LI
;
Jinsong LI
Author Information
1. 湖北省药品监督检验研究院生物安全中心(武汉 430075)
- Keywords:
Atopic dermatitis;
Type 2 inflammation;
Skin barrier;
Skin flora;
Biological agents;
Natural medicines
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(4):449-460
- CountryChina
- Language:Chinese
-
Abstract:
Atopic dermatitis(AD)is a chronic,relapsing,inflammatory dermatosis.It is an inflammatory chronic dermatosis,often associated with other atopic manifestations,that can affect both children and adults.Multiple studies have shown that people with AD have a higher burden of disease,with important implications for public health.At present,a large number of studies at home and abroad have shown that the pathogenesis of AD involves skin immune inflammation,skin barrier and skin flora,proposing that the impaired epidermal permeability barrier function is an important link in the pathogenesis of AD,therefore,repairing and protecting the skin barrier function,and maintaining the skin microecological balance are particularly important for the treatment of AD.The treatment of AD involves a number of aspects such as basic treatment,topical medication,physiotherapy and systemic medication.For mild to moderate patients,on the basis of basic treatment,topical medications and oral antihistamines can be used.For moderate to severe patients,systemic therapy is an option.Some innovative therapies represented by biologic have made important progress,which can effectively inhibit type 2 inflammation and help patients achieve long-term disease control.Meanwhile,the mining and development of natural medicines is also receiving increasing attention and will provide more options for the treatment of AD patients.
